Allogene Therapeutics Inc.（纳斯达克代码：ALLO）今日披露了其关键性ALPHA3试验的中期无效性分析数据。研究显示，在一线巩固治疗大B细胞淋巴瘤（LBCL）患者中，实验性疗法Cemacabtagene Ansegedleucel（简称Cema-Cel）展现出显著优势。
具体数据显示，接受Cema-Cel治疗的患者组中，微小残留病灶（MRD）清除率达到58.3%。这一结果远高于观察组的16.7%，凸显了该细胞疗法的潜在疗效。试验结果为进一步评估Cema-Cel在淋巴瘤治疗领域的应用价值提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.